CN104114156A - 冻干脂质体 - Google Patents

冻干脂质体 Download PDF

Info

Publication number
CN104114156A
CN104114156A CN201280059606.1A CN201280059606A CN104114156A CN 104114156 A CN104114156 A CN 104114156A CN 201280059606 A CN201280059606 A CN 201280059606A CN 104114156 A CN104114156 A CN 104114156A
Authority
CN
China
Prior art keywords
compositions
liposome
liposomes
reconstruct
lyophilization
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280059606.1A
Other languages
English (en)
Chinese (zh)
Inventor
D·卡波拉尔-莉利
L·马耶尔
P·塔迪
D·瓦金斯
Y·曾
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jazz Pharmaceuticals Therapeutics Inc
Original Assignee
Celator Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48141268&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN104114156(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celator Pharmaceuticals Inc filed Critical Celator Pharmaceuticals Inc
Priority to CN201810733439.3A priority Critical patent/CN108853031A/zh
Publication of CN104114156A publication Critical patent/CN104114156A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
CN201280059606.1A 2011-10-21 2012-10-15 冻干脂质体 Pending CN104114156A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810733439.3A CN108853031A (zh) 2011-10-21 2012-10-15 冻干脂质体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161550047P 2011-10-21 2011-10-21
US61/550,047 2011-10-21
PCT/US2012/060293 WO2013059133A1 (en) 2011-10-21 2012-10-15 Lyophilized liposomes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201810733439.3A Division CN108853031A (zh) 2011-10-21 2012-10-15 冻干脂质体

Publications (1)

Publication Number Publication Date
CN104114156A true CN104114156A (zh) 2014-10-22

Family

ID=48141268

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201280059606.1A Pending CN104114156A (zh) 2011-10-21 2012-10-15 冻干脂质体
CN201810733439.3A Pending CN108853031A (zh) 2011-10-21 2012-10-15 冻干脂质体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201810733439.3A Pending CN108853031A (zh) 2011-10-21 2012-10-15 冻干脂质体

Country Status (22)

Country Link
US (5) US10028912B2 (enExample)
EP (2) EP2768484B1 (enExample)
JP (6) JP6133308B2 (enExample)
KR (5) KR20220141906A (enExample)
CN (2) CN104114156A (enExample)
AU (1) AU2012326370C9 (enExample)
BR (1) BR112014009305B1 (enExample)
CA (1) CA2852777C (enExample)
DK (1) DK2768484T3 (enExample)
ES (1) ES2750368T3 (enExample)
FR (1) FR19C1063I2 (enExample)
HR (1) HRP20191683T1 (enExample)
HU (2) HUE045978T2 (enExample)
IL (1) IL232161B (enExample)
LU (1) LUC00135I2 (enExample)
NL (1) NL301016I2 (enExample)
NO (1) NO2019041I1 (enExample)
PL (1) PL2768484T3 (enExample)
PT (1) PT2768484T (enExample)
RU (1) RU2648753C2 (enExample)
SI (1) SI2768484T1 (enExample)
WO (1) WO2013059133A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115252563A (zh) * 2022-06-24 2022-11-01 石药集团中奇制药技术（石家庄）有限公司 一种柔红霉素阿糖胞苷脂质体冻干品的制备方法
US11980636B2 (en) 2020-11-18 2024-05-14 Jazz Pharmaceuticals Ireland Limited Treatment of hematological disorders

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104114156A (zh) * 2011-10-21 2014-10-22 切拉托尔制药公司 冻干脂质体
KR102507789B1 (ko) 2014-08-28 2023-03-07 더 제너럴 하스피탈 코포레이션 주입가능한 슬러리 및 이를 제조하고 사용하는 방법
US11471401B2 (en) 2014-08-28 2022-10-18 The General Hospital Corporation Injectable slurries and methods of manufacturing the same
US11504322B2 (en) 2014-08-28 2022-11-22 The General Hospital Corporation Injectable slurries and methods of manufacturing the same
US11298318B2 (en) * 2015-04-13 2022-04-12 Fountain Technologies International, Llc One-step method for production of ultra-small lipid structures
DK3324932T3 (da) 2015-07-22 2021-04-06 Nitto Denko Corp Sammensætninger og fremgangsmåder for nanopartikel lyofile former
JP6976941B2 (ja) * 2015-11-11 2021-12-08 セレーター ファーマシューティカルズ インコーポレイテッド 白血病に罹患している対象の治療レジメンを選択するためのアッセイ及び方法
US11564830B2 (en) 2016-02-26 2023-01-31 The General Hospital Corporation Medical ice slurry production and delivery systems and methods
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
CA3069019A1 (en) * 2017-07-10 2019-01-17 Immunovaccine Technologies Inc. Pharmaceutical compositions, methods for preparation using lipid vesicle particles of defined size, and uses thereof
CN113164502A (zh) 2018-09-25 2021-07-23 塞拉特药物股份有限公司 血液病的低强度治疗
AU2020231916B2 (en) 2019-03-01 2025-08-28 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
CA3144443A1 (en) * 2019-06-28 2020-12-30 Moleculin Biotech, Inc. Method of reconstituting liposomal annamycin
JP2022542571A (ja) * 2019-07-24 2022-10-05 ザ ジェネラル ホスピタル コーポレイション カプセル化により異なる凝固点を有する物質を作製する方法
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
CN116003493B (zh) * 2022-12-16 2025-02-28 常州金远药业制造有限公司 一种二价铜离子及阿糖胞苷的回收方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110002982A1 (en) * 2001-11-13 2011-01-06 Paul Tardi Lipid carrier compositions with enhanced blood stability

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880635B1 (en) * 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
US5077056A (en) 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
EP0208764A4 (en) 1985-01-11 1987-10-08 Univ California METHOD FOR PRESERVING LIPOSOMES.
CA1256372A (en) 1985-04-11 1989-06-27 Koichiro Miyazima Process for producing liposome composition
US4927571A (en) 1987-05-18 1990-05-22 Liposome Technology, Inc. Preparation of injectable doxorubicin/liposome suspension
US4915951A (en) 1987-12-03 1990-04-10 California Institute Of Technology Cryoprotective reagent
FI902249A0 (fi) * 1988-10-05 1990-05-04 Vestar Inc Foerfarande foer framstaellning av liposomer med foerbaettrad stabilitet under torkning.
US5049392A (en) * 1989-01-18 1991-09-17 The Liposome Company, Inc. Osmotically dependent vesicles
ATE237362T1 (de) 1996-02-19 2003-05-15 Amersham Health As Thermostabilisiertes kontrastmittel
IT1289938B1 (it) 1997-02-20 1998-10-19 Angelini Ricerche Spa Preparazione farmaceutica comprendente liposomi liofilizzati in cui e' incapsulato un principio attivo altamente insolubile in acqua e
GB9813100D0 (en) 1998-06-18 1998-08-19 Secr Defence Method of forming liposomes
ES2225178T3 (es) 1999-07-16 2005-03-16 Alza Corporation Composicion liposomica resistente a los daños producidos por congelacion/descongelacion.
US6984395B2 (en) * 2001-04-11 2006-01-10 Qlt, Inc. Drug delivery system for hydrophobic drugs
ATE475411T1 (de) 2001-10-03 2010-08-15 Celator Pharmaceuticals Inc Liposomenladung mit metallionen
US7850990B2 (en) * 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
US20050118249A1 (en) 2001-11-13 2005-06-02 Murray Webb Lipid carrier compositions and methods for improved drug retention
EP1585504A4 (en) 2002-11-06 2009-07-15 Azaya Therapeutics Inc Protein stabilized liposomal formulations of pharmaceutical active ingredients
CN1798544A (zh) * 2003-04-02 2006-07-05 塞拉特药物股份有限公司 喜树碱和氟嘧啶的组合物
AU2005235455B2 (en) 2004-04-22 2011-01-20 Jazz Pharmaceuticals Therapeutics, Inc. Liposomal formulations of anthracycline agents and cytidine analogs
US7893338B2 (en) * 2004-07-15 2011-02-22 Creative Technology Ltd Method of composing music on a handheld device
CA2584583A1 (en) * 2004-10-28 2006-05-11 Alza Corporation Lyophilized liposome formulations and method
US20090285878A1 (en) * 2004-11-05 2009-11-19 Tekmira Pharmaceuticals Corporation Compositions and methods for stabilizing liposomal drug formulations
CA2587741A1 (en) 2004-11-18 2006-05-26 Celator Pharmaceuticals, Inc. Method for loading multiple agents into delivery vehicles
WO2007050784A2 (en) 2005-10-25 2007-05-03 Celator Pharmaceuticals, Inc. Fixed ratio drug combination treatments for solid tumors
EP1976485A4 (en) 2005-12-22 2011-10-26 Celator Pharmaceuticals Inc LIPOSOMAL FORMULATIONS WITH SECONDARY AND TERTIARY AMINES AND METHOD OF MANUFACTURING THEREOF
US8092828B2 (en) * 2007-02-16 2012-01-10 Celator Pharmaceuticals, Inc. Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders
EP2187869B1 (en) 2007-08-17 2015-10-14 Celator Pharmaceuticals, Inc. Improved platinum drug formulations
CN101878024B (zh) 2007-11-28 2014-04-09 塞拉特药物股份有限公司 改良的紫杉烷递送系统
ES2704986T3 (es) 2008-10-16 2019-03-21 Celator Pharmaceuticals Inc Combinaciones de una camptotecina liposomal soluble en agua con cetuximab o bevacizumab
WO2011066684A1 (zh) 2009-12-03 2011-06-09 江苏恒瑞医药股份有限公司 伊立替康或盐酸伊立替康脂质体及其制备方法
US20130052259A1 (en) 2010-02-01 2013-02-28 Yechezkel Barenholz Liposomes comprising amphipathic drugs and method for their preparation
CN104114156A (zh) * 2011-10-21 2014-10-22 切拉托尔制药公司 冻干脂质体

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110002982A1 (en) * 2001-11-13 2011-01-06 Paul Tardi Lipid carrier compositions with enhanced blood stability

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11980636B2 (en) 2020-11-18 2024-05-14 Jazz Pharmaceuticals Ireland Limited Treatment of hematological disorders
CN115252563A (zh) * 2022-06-24 2022-11-01 石药集团中奇制药技术（石家庄）有限公司 一种柔红霉素阿糖胞苷脂质体冻干品的制备方法
CN115252563B (zh) * 2022-06-24 2024-07-12 石药集团中奇制药技术（石家庄）有限公司 一种柔红霉素阿糖胞苷脂质体冻干品的制备方法

Also Published As

Publication number Publication date
JP2018150342A (ja) 2018-09-27
EP2768484B1 (en) 2019-07-24
JP2017160211A (ja) 2017-09-14
JP7476161B2 (ja) 2024-04-30
JP6133308B2 (ja) 2017-05-24
RU2018107407A3 (enExample) 2021-05-04
US20210169803A1 (en) 2021-06-10
NL301016I2 (nl) 2020-04-16
EP3572071A1 (en) 2019-11-27
HRP20191683T1 (hr) 2019-12-13
US10835492B2 (en) 2020-11-17
AU2012326370A2 (en) 2014-06-12
RU2014120475A (ru) 2015-11-27
US20190070112A1 (en) 2019-03-07
IL232161A0 (en) 2014-05-28
KR102284689B1 (ko) 2021-08-02
LUC00135I1 (enExample) 2019-10-25
HUS1900047I1 (hu) 2019-11-28
WO2013059133A1 (en) 2013-04-25
DK2768484T3 (da) 2019-10-07
ES2750368T3 (es) 2020-03-25
EP2768484A1 (en) 2014-08-27
JP2014532623A (ja) 2014-12-08
FR19C1063I1 (fr) 2019-11-22
AU2012326370C1 (en) 2023-03-30
NL301016I1 (nl) 2019-10-30
HUE045978T2 (hu) 2020-01-28
KR102113753B1 (ko) 2020-05-21
JP2022033892A (ja) 2022-03-02
KR20210095746A (ko) 2021-08-02
SI2768484T1 (sl) 2019-12-31
US20230172855A1 (en) 2023-06-08
CA2852777A1 (en) 2013-04-25
BR112014009305A2 (pt) 2017-04-11
US10028912B2 (en) 2018-07-24
US20180161273A1 (en) 2018-06-14
AU2012326370C9 (en) 2023-05-18
LUC00135I2 (enExample) 2021-02-12
KR20190111139A (ko) 2019-10-01
KR102452305B1 (ko) 2022-10-07
KR20200057104A (ko) 2020-05-25
US20140255475A1 (en) 2014-09-11
EP2768484A4 (en) 2015-04-22
JP2024045183A (ja) 2024-04-02
KR20220141906A (ko) 2022-10-20
CN108853031A (zh) 2018-11-23
JP6592556B2 (ja) 2019-10-16
IL232161B (en) 2019-07-31
FR19C1063I2 (fr) 2020-10-30
PT2768484T (pt) 2019-10-28
HK1201039A1 (en) 2015-08-21
RU2018107407A (ru) 2019-02-25
AU2012326370B2 (en) 2017-06-01
JP2020007367A (ja) 2020-01-16
BR112014009305B1 (pt) 2023-01-24
CA2852777C (en) 2020-10-27
AU2012326370A1 (en) 2014-06-05
RU2648753C2 (ru) 2018-03-28
NO2019041I1 (no) 2019-11-25
JP6359717B2 (ja) 2018-07-18
KR102024836B1 (ko) 2019-09-24
KR20140092323A (ko) 2014-07-23
PL2768484T3 (pl) 2019-12-31
US10166184B2 (en) 2019-01-01

Similar Documents

Publication Publication Date Title
US20230172855A1 (en) Method of lyophilizing liposomes
KR101209496B1 (ko) 나노입자 제제를 보관하는 방법
RU2780489C2 (ru) Лиофилизированные липосомы
HK1201039B (en) Lyophilized liposomes

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20141022

RJ01 Rejection of invention patent application after publication